Action Adaptive Biotechnologies (ADPT)
Entreprise du secteur de la santé. Voici le cours, un aperçu de l'activité et l'essentiel à savoir sur Adaptive Biotechnologies en septembre 2026.
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Performance de croissance sur six mois
Aperçu de la performance de l'action
Note des analystes
Analysts recommend buying Adaptive Biotechnologies' stock, expecting it to increase in value.
Santé financière
Adaptive Biotechnologies is generating strong revenue and cash flow, supported by a high gross margin.
Voyez plus d'actions en téléchargeant l'application GRATUITEMENT
Cela ne prend que 60 secondes.
Pourquoi investir avec Nemo ?
Zéro commission
Négociez actions, ETF et plus encore sans commission. Gardez une plus grande part de vos gains.
Fiable et réglementé
Membre du groupe Exinity depuis 2015, au service de plus d'un million de clients dans le monde.